Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
A Trial Investigating NN1218 in Subjects With Type 1 Diabetes
Phase 1
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2010-05-12
- Last Posted Date
- 2013-12-10
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 26
- Registration Number
- NCT01121289
A Trial Investigating NN1218 in Subjects With Type 1 and Type 2 Diabetes
Phase 1
Completed
- Conditions
- Diabetes Mellitus, Type 2DiabetesDiabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2010-05-12
- Last Posted Date
- 2017-01-18
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 82
- Registration Number
- NCT01121276
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Chula Vista, California, United States
A Trial Evaluating the Effect of NN1250 at Steady State Conditions in Subjects With Type 1 Diabetes
Phase 1
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2010-05-03
- Last Posted Date
- 2017-10-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 66
- Registration Number
- NCT01114542
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany
Observational Study of the Safety and Efficacy of Norditropin® in Patients With SGA (Small for Gestational Age) Short Stature That Are Still Growing
- First Posted Date
- 2010-04-27
- Last Posted Date
- 2019-01-11
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 227
- Registration Number
- NCT01110928
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan
Observational Study of the Safety and Efficacy of Norditropin® in Adult Patients With Growth Hormone Deficiency
Completed
- Conditions
- Adult Growth Hormone DeficiencyGrowth Hormone Disorder
- Interventions
- First Posted Date
- 2010-04-22
- Last Posted Date
- 2015-01-08
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 387
- Registration Number
- NCT01109017
A Two Part Trial Investigating the Safety of NN9925 in Healthy Male Subjects
Phase 1
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2Healthy
- Interventions
- Drug: NN9925 (oral)Drug: NN9925 (i.v.)Drug: placebo
- First Posted Date
- 2010-03-16
- Last Posted Date
- 2017-02-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 70
- Registration Number
- NCT01087645
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Nottingham, United Kingdom
Comparison of Two Vaginal Tablets, Produced at Different Sites, in Postmenopausal Women With Atrophic Vaginitis
Phase 1
Completed
- Conditions
- MenopausePostmenopausal Vaginal Atrophy
- Interventions
- Drug: estradiol, 25 mcg
- First Posted Date
- 2010-03-12
- Last Posted Date
- 2014-06-26
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 70
- Registration Number
- NCT01085877
Comparison of a Blood Clotting Drug (Recombinant Factor XIII) Produced by Two Different Manufacturers in Healthy Male Subjects
Phase 1
Completed
- Conditions
- Congenital Bleeding DisorderCongenital FXIII DeficiencyHealthy
- Interventions
- First Posted Date
- 2010-03-08
- Last Posted Date
- 2016-09-21
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 51
- Registration Number
- NCT01082406
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Harrow, United Kingdom
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2010-03-03
- Last Posted Date
- 2017-02-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 493
- Registration Number
- NCT01079234
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Welwyn Garden City, United Kingdom
An Observational Study Investigating the Safety and Effectiveness of Repaglinide in Chinese Patients
- First Posted Date
- 2010-03-01
- Last Posted Date
- 2014-06-26
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 2033
- Registration Number
- NCT01077570
© Copyright 2025. All Rights Reserved by MedPath